Bailard, Inc. Arcus Biosciences, Inc. Transaction History

Bailard, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 31, 2020	SELL	$7.33 - $10.79 $97,489 - $143,507	-13,300 Closed	0 $0
Q3 2019 Oct 18, 2019	SELL	$6.44 - $10.18 $161,000 - $254,500	-25,000 Reduced 65.27%	13,300 $121,000
Q1 2019 Apr 24, 2019	BUY	$8.95 - $12.49 $119,034 - $166,117	13,300 Added 53.2%	38,300 $478,000
Q4 2018 Feb 05, 2019	BUY	$9.74 - $14.5 $243,500 - $362,500	25,000 New	25,000 $269,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.